Failure to remit at endpoint · patients with depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to remit at endpoint · patients with depression
Paroxetine showed no clear difference in failure to remit at endpoint compared with older ADs (low certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with citalopram (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with citalopram (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with duloxetine (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to remit at endpoint · patients with depression
Paroxetine showed no clear difference in failure to remit at endpoint compared with duloxetine (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with duloxetine (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with duloxetine (moderate certainty).
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with escitalopram (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · depression
Paroxetine showed no clear difference in failure to respond at 16‐24 weeks compared with escitalopram (moderate certainty).
1 finding from 1 review
Failure to remit at endpoint · depression
Paroxetine showed no clear difference in failure to remit at endpoint compared with escitalopram (low certainty).
1 finding from 1 review
SMD at endpoint · depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with escitalopram (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with escitalopram (moderate certainty).
1 finding from 1 review